Skip to content

Noninvasive Cardiac Imaging in Vasospastic Angina Korean Registry (NAVIGATOR)

Dual-acquisition of Noninvasive Cardiac Imaging in Vasospastic Angina Korean Registry

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03570671
Acronym
NAVIGATOR
Enrollment
90
Registered
2018-06-27
Start date
2018-03-01
Completion date
2021-07-01
Last updated
2020-08-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Spasm

Keywords

MDCTA, Coronary artery spasm

Brief summary

With regard to the characteristics of spasm segment, had been clearly described by other invasive imaging methods including intravascular ultrasound and optical coherence tomography. However, there is potential risk during these invasive procedures, such as severe myocardial ischemia or fatal arrhythmia. Presently available imaging test for coronary artery disease in multi detector-row computed tomography angiography (MDCTA) evaluation has high diagnostic accuracy to evaluate coronary artery stenosis. However, previous report assessing imaging findings or diagnostic accuracy of MDCTA in patients with vasospastic angina (VSA) is lacking.

Detailed description

Previously investigators analyzed the characteristics of coronary spasm segment in an observational individual dataset, suspected VSA patients (n=20) underwent dual-acquisition of MDCTA (initial and intravenous nitrate injected CT imaging), the diagnostic accuracy showed sensitivity: 73%, specificity: 100%, positive predictive value: 100%, and negative predictive value: 56%. Further study is necessary because previous analysis presented limited sample size and deficiency of healthy control. Therefore, investigators hypothesis that dual-acquisition of MDCTA in noninvasive tool for coronary assessment provide more information of coronary characteristics, and the diagnostic efficacy would be non-inferior as compared with the invasive coronary imaging modality in coronary spasm-induced angina attacks.

Interventions

DIAGNOSTIC_TESTSpasm positive

Investigators define the positive criteria for VSA on MDCTA as follows: 1. Significant stenosis (≥ 50%) with negative remodeling but no definite evidence of plaques, which completely dilated on IV nitrate CT, or 2. Diffuse small diameter (\< 2mm) of a major coronary artery with beaded appearance which completely dilated on IV nitrate CT.

DIAGNOSTIC_TESTSpasm negative

Suspected vasospastic angina subjects with negative MDCTA-derived VSA are considered as reference modality.

Sponsors

Dong-A University
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
DIAGNOSTIC
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
20 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* Subject is onset of angina-like attack at rest, during effort, or during rest and effort. * Subject has chest pain between night and early morning. * Subject is scheduled to undergo MDCTA. * Subject is an acceptable candidate for CAG with an EG provocation test. * Cardiac condition: BP\>90/60mmHg, ECG: sinus rhythm with regular, left ventricular ejection fraction\>55%, and resting heart rate\<100 beats/min. * Subject will be provided written informed consent. * Subject is willing to comply with study follow-up requirement.

Exclusion criteria

* Subject has clinical evidence of acute coronary syndrome. * Subject has evidence of significant narrowing (\>50% stenosis by CAG). * Subject has clinical evidence of cardiomyopathy or valvular heart disease. * Subject is hemodynamically unstable. * Subject has a history of PCI and CABG. * Subject is pregnant and/or breastfeeding or intends to become pregnant during the duration of the study. * Subject has known allergy to contrast medium. * Subject has renal insufficiency (serum creatine \>2.5 mg/dl).

Design outcomes

Primary

MeasureTime frameDescription
Safety and Tolerability3 daysMDCTA procedure: all subjects will undergo MDCTA without a vasodilator (initial CT) in the early morning before the ergonovine provocation spasm test. Subsequent IV nitrate CT will be allowed at a 3-day washout period after the first contrast usage. The scan protocol for the IV nitrate CT is as follows: during continuous injection of the intravenous vasodilating agent (isosorbidedinitrate 2 mg/hr), blood pressure will be checked every 2 minutes. When both the systolic and diastolic blood pressure decrease by 10 mmHg in comparison to the initial value, the CT scan initiate and images will be acquired during the nitrate infusion. Investigators define the positive criteria for VSA on MDCTA as follows: 1. Significant stenosis (≥ 50%) with negative remodeling but no definite evidence of plaques, which completely dilated on IV nitrate CT, or 2. Diffuse small diameter (\< 2mm) of a major coronary artery with beaded appearance which completely dilated on IV nitrate CT.

Secondary

MeasureTime frameDescription
Coronary vessel distensibility3 daysTo evaluate the extent of coronary vessel distensibility by dual-acquisition of cardiac MDCTA in patients with VSA
Cutoff value of coronary vessel distensibility index3 daysTo consider the cutoff value of coronary vessel distensibility index (CVDI) to predict the coronary spasm induced angina-like attacks. Investigators define the CVDI as following formulas: 1. CVDI-CSA (cross-section area)= \[(CSA\_IV nitrate - CSA\_initial) / CSA\_IV nitrate\]ⅹ100% or 2. CVDI-D (diameter)= \[(D\_IV nitrate - D\_initial) / D\_IV nitrate\]ⅹ100%.
Incidence of multi-vessel spasm3 daysTo examine the incidence of multi-vessel coronary spasm by MDCTA.
Diagnostic accuracy of MDCTA3 daysTo determine the diagnostic accuracy of MDCTA modalities for detection of VSA.
Characteristics of spasm-related coronary artery segment3 daysTo describe the characteristics of spasm-related coronary artery segment including vessel remodeling, plaque composition and stenosis degree.

Countries

South Korea

Contacts

Primary ContactMoo Hyun Kim, MD
kimmh@dau.ac.kr+82-51-240-2976
Backup ContactCai De Jin, MD
jincaide1118@163.com+86-178-0250-2582

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026